Cargando…
Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
Personalised medicine, an essential component of modern thoracic oncology, has been evolving continuously ever since the discovery of the epidermal growth factor receptor and its tyrosine kinase inhibitors. Today, screening for driver alterations in patients with advanced lung adenocarcinoma as well...
Autores principales: | Abdayem, Pamela, Planchard, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489045/ https://www.ncbi.nlm.nih.gov/pubmed/34289984 http://dx.doi.org/10.1183/16000617.0294-2020 |
Ejemplares similares
-
Personalised medicine for nonsmall cell lung cancer
por: Mascaux, Céline, et al.
Publicado: (2017) -
Bronchoscopic treatment of inoperable nonsmall cell lung cancer
por: Kniese, Christopher M., et al.
Publicado: (2020) -
How to handle oligometastatic disease in nonsmall cell lung cancer
por: Eichhorn, Florian, et al.
Publicado: (2021) -
New developments in locally advanced nonsmall cell lung cancer
por: Huber, Rudolf M., et al.
Publicado: (2021) -
Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series “Pathology for the clinician” Edited by Peter Dorfmüller and Alberto Cavazza
por: Bubendorf, Lukas, et al.
Publicado: (2017)